Prodotto aggiunto correttamente al carrello.

discount label
H-LPPVVAKEI-OH
Visualizzare in 3D

Biosynth logo

H-LPPVVAKEI-OH

Rif. 3D-PP46924

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024

Informazioni sul prodotto

Nome:
H-LPPVVAKEI-OH
Sinonimi:
  • NH2-Leu-Pro-Pro-Val-Val-Ala-Lys-Glu-Ile-OH
Descrizione:

Peptide H-LPPVVAKEI-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-LPPVVAKEI-OH include the following: Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101+ patients protected mice against chimaeric ecotropic HIV-1 challenge Y Roshorm , JP Hong, N Kobayashi - European journal of , 2009 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200939309 Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape Y Liu, J McNevin, H Zhao, DM Tebit, RM Troyer - Journal of , 2007 - Am Soc Microbiolhttps://journals.asm.org/doi/abs/10.1128/JVI.01277-07 An in silico Approach for Epitope Based Vaccine Design Against Ebola virus S Radhakrishnan, ME Sobhia - Archives of Microbiology & , 2021 - fortuneonline.orghttps://fortuneonline.org/articles/an-in-silico-approach-for-epitope-based-vaccine-design-against-ebola-virus.html Mining the Mycobacterium tuberculosis proteome for identification of potential T-cell epitope based vaccine candidates R Madan , K Pandit , L Bhati, H Kumar, N Kumari - Microbial , 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0882401021002680 Principles and aspects of molecular docking: A bird's eye view R Madan , K Pandit , H Kumar, N Kumari - Hans Shodh , 2020 - hansshodhsudha.comhttps://www.hansshodhsudha.com/first-second-issues/New%20Hansraj%20College%20Book-1-110-121.pdf Longitudinal analysis of an HLA-B* 51-restricted epitope in integrase reveals immune escape in early HIV-1 infection N Yager, N Robinson, H Brown, P Flanagan , J Frater - AIDS, 2013 - journals.lww.comhttps://journals.lww.com/aidsonline/fulltext/2013/01280/longitudinal_analysis_of_an_hla_b_51_restricted.2.aspx Nonstandard Peptide Binding Revealed by M Takiguchi, DI Stuart , EY Jones , K Maenaka - J , 2000 - researchgate.nethttps://www.researchgate.net/profile/David_Stuart4/publication/12346091_Nonstandard_Peptide_Binding_Revealed_by_Crystal_Structures_of_HLA-B5101_Complexed_with_HIV_Immunodominant_Epitopes/links/56d4296608ae2ea08cf8db44/Nonstandard-Peptide-Binding-Revealed-by-Crystal-Structures-of-HLA-B5101-Complexed-with-HIV-Immunodominant-Epitopes.pdf Molecular dynamics simulations provide molecular insights into the role of HLA-B51 in Behaca§et's disease pathogenesis M Gur , M Golcuk , A Gul, B Erman - Chemical Biology & Drug , 2020 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/cbdd.13658 Analysis of the DosR regulon genes to select cytotoxic T lymphocyte epitope specific vaccine candidates using a reverse vaccinology approach K Pandey , M Sharma , I Saarav, S Singh , P Dutta - International Journal of , 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2212553115001594 Nonstandard peptide binding revealed by crystal structures of HLA-B* 5101 complexed with HIV immunodominant epitopes K Maenaka, T Maenaka, H Tomiyama - The Journal of , 2000 - journals.aai.orghttps://journals.aai.org/jimmunol/article/165/6/3260/69809 aca”aca˜ aca
 aca’aca™aca— aca– aca”aca˜ I Saraav, K Pandey, M Sharma, S Singh, P Dutta - 2016 - academia.eduhttps://www.academia.edu/download/94032635/j.meegid.2016.07.00420221110-1-56hyo2.pdf Predicting promiscuous antigenic T cell epitopes of Mycobacterium tuberculosis mymA operon proteins binding to MHC Class I and Class II molecules I Saraav, K Pandey , M Sharma , S Singh , P Dutta - Infection, Genetics and , 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1567134816302829 Quantification of HIV-1-specific T-cell responses at the mucosal cervicovaginal surface. DP wOOLEY, P KT, T RJ, P CC, B MA - Aids, 2000 - search.proquest.comhttps://search.proquest.com/openview/67df1d0818c025701edfd260f85c5c2c/1?pq-origsite=gscholar&cbl=32744

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP46924 H-LPPVVAKEI-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".